Table 3 Characteristics of 58 Myeloid Cases Associated With t(3;12) Reported In The Literature.

From: Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities

Case #

Reference

Age/Sex

Diagnosis

Karyotype

# CG Abn

BM Blasts (%)

PB Blasts (%)

WBC (109/L)

Hgb (g/dL)

Plt (109/L)

SCT

EVI1 FISH

ETV6 FISH

OS (mo)

1

AChkar

63/F

AMML

47,XX,+8,t(3;12)(q26;p13)[18]/47,XX,+8[2]

2

ND

ND

5.4

9.61

132

ND

Positive

Positive

2

4

Beyer

29/M

AML (NOS)

46,XY,t(3;12)(q26;p13)[12]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

7

Bobadilla

61/M

AML w/ mat

46,XY,t(3;12)(q26.2;p13)[20]

1

ND

ND

ND

ND

ND

ND

Positive

ND

ND

8

Bobadilla

37/M

AML w/o mat

46,XY,t(3;12)(q26.2;p13)[19]/46,idem,der(9)t(1;9)(q10;p10)[2]

> 3

ND

ND

ND

ND

ND

ND

Positive

ND

ND

9

Bobadilla

53/F

AML (NOS)

46,XX,t(3;12)(q26.2;p13)[20]

1

ND

ND

ND

ND

ND

ND

Positive

ND

ND

10

Dastugu

67/F

Acute Meg Leuk

46,XX,t(3;12)(q26;p13)[20]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

11

Haferlach

74/M

AML (NOS)

46,XY,t(3;12)(q26;p13)[20]

1

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

12

Haferlach

27/M

AML (NOS)

46,XY,t(3;12)(q26;p13)[4]/46,XY[2]

1

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

13

Haferlach

61/F

AML-MRC

46,XX,t(3;12)(q26;p13),del(5)(q14q34)[20]

2

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

14

Haferlach

77/F

AML-MRC

46,XX,t(3;12)(q26;p13),del(5)(q14q34)[3]/46,XX[4]

2

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

15

Haferlach

67/F

AML (NOS)

46,XX,t(3;12)(q26;p13)[10]/46,XX[1]

1

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

16

Haferlach

48/M

t-AML

45,XY,t(3;12)(q26;p13),-7[9]/46,XY[12]

2

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

17

Haferlach

50/M

AML-MRC

45,XY,t(3;12)(q26;p13),-7[5]/46,XY[15]

2

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

20

Haferlach

48/F

AML-MRC

46,XX,der(5)t(5;6)(q14;p22),der(6)t(6;7)(p22;q?),der(7)t(5;7)(q?;q11),der(12)t(3;12)(q26;p13)[3]/47,XX,der(5)t(5;6)(q14;p22),der(6)t(6;7)(p22;q?),der(7)t(5;7)(q?;q11),der(12)t(3;12)(q26;p13),+21[9]

> 3

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

21

Hazard

13/F

AML w/ mat

45,XX, t(3;12)(q26;p13),-7

2

37

10

6.5

8.2

79

Yes

ND

ND

10

22

Iwase

46/M

AMML

46,XY, t(3;12)(q26;p13)

1

54

53

53.8

6.9

765

ND

ND

ND

6

23

Kim

60/M

t-AML

45,XY, t(3;12)(q26;p13),-7[16]

2

26

16

4.45

6

68

ND

Positive

Positive

ND

24

Langabeer

?/M

AML (NOS)

46,XY, t(3;12)(q26;p13) [20]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

25

Lavallee

41/F

AML-MRC

46,XX,t(3;12)(q26.2;p13)[2]/ 45,idem, -7[20]

2

ND

ND

ND

ND

ND

ND

ND

ND

ND

26

Lugthart

?/F

AML (NOS)

46,XX,t(3;12)(q26;p13)[20]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

27

Lugthart

?/F

AML (NOS)

46,XX,t(3;12)(q26;p13)[18]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

28

Lugthart

?/M

AML (NOS)

46,XY,t(3;12)(q26;p13)[55]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

29

Lugthart

?/M

AML (NOS)

46,XY,t(3;12)(q26;p13)[20]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

30

Lugthart

?/M

AML (NOS)

46,XY,t(3;12)(q26;p13)[7]/47,idem,+18[4]/46,XY[8]

2

ND

ND

ND

ND

ND

ND

ND

ND

ND

31

Lugthart

?/F

AML (NOS)

46,XX,t(3;12)(q26;p13)[13]/46,XX[7]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

32

Lugthart

?/F

AML (NOS)

46,XX,t(3;12)(q26;p13)[12]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

33

Lugthart

?/F

AML (NOS)

46,XX,t(3;12)(q26;p13)[20]

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

34

Lugthart

?/F

AML (NOS)

46,XX,t(3;12)(q26;p13)

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

35

Lugthart

?/M

AML (NOS)

46,XY,t(3;12)(q26;p13)

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

56

Yamamoto

45/M

AML-MRC

46,XY,t(3;12)(q26.2;p13),add(7)(p13), add(12)(p11.2)[18]/46,XY,t(3;12;5)(q26.2;p13;q31),add(7)(p13), add(12)(p11.2)[2] Later: 46,XY,t(3;12)(q26.2;p13), t(7;12)(p15;p13)[5]/46,sl,t(2;10)(p23;q22)[3]

> 3

39

35

9.1

9.6

26

Yes

ND

Positive

18

37

Nishimura

49/F

AML w/o mat

46,XX,t(3;12)(q26.2;p13),add(7)(q11)

2

65.4

65

6.3

6.5

46

ND

ND

ND

19

41

Peeters

33/F

AML-MRC

46,XX,t(3;12)(q26;p13),del(7)(q22)

2

16.2

8

21.8

11.1

311

ND

Positive

Positive

6

42

Poppe

41/M

AML-MRC

45,XY,t(3;12)(q26;p13),-7

2

ND

ND

ND

ND

ND

ND

ND

ND

ND

43

Poppe

52/M

AML-MRC

46,XY,t(3;12)(q26;p13),-7,+r

> 3

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

44

Raynaud

60/M

AML-MRC

46,XY,t(3;12)(q26;p13),de1(7)(q2lq35)[20]

2

44

4

2.2

9.6

174

ND

Positive

Positive

7

45

Raynaud

87/M

AML-MRC

46,XY,t(3;12)(q26;pl3),deI(7)(q21;q34)[19]/46,XY,t(3;12)(q26;p13)[1]

2

61

35

3.3

8.8

113

ND

Positive

Positive

10

46

Raynaud

28/F

AML-MRC

46,XX,t(3;12)(q26.2;p13)[30]; 3 years later: 46,XX,t(1;7)(p13;p15),t(3;12)(q26;p13),-6,del(11)(q21q23),der(11)t(11;?)(p11;?),add(17)(p11),del(17)(p12),der(19)t(12;19)(q 13;q13),+der(?)t(?;14)(?;q11)[11]

1

46

30

37

11.1

34

Yes

Positive

Positive

12

47

Raynaud

26/M

Acute Meg Leuk

46,XY,?int del(1)(p32p34),t(3;12)(q26;p13)[15]/46,idem,de1(5)(p1?4) [15]

> 3

66

25

8.6

9.7

192

ND

Positive

Positive

7

49

Roumier

57/M

AML w/o mat

46,XY,t(3;12)(q26;p13).ish der(3)(ETV6+)der(12)(ETV6+)[15]/46,XY[7]

> 3

ND

ND

ND

ND

ND

ND

ND

ND

15

50

Secker-Walker

27/F

AML-MRC

46,XX,t(3;12)(q26;p13)

1

ND

ND

ND

ND

110

Yes

ND

ND

39

51

Secker-Walker

24/M

AML-MRC

46,XY,del(1)(p3?2p3?4),t(3;12)(q26;p13)

2

ND

ND

ND

ND

192

ND

ND

ND

ND

52

Shali

59/F

AMML

46,XX,t(3;12)(q26;p13)[8]/46,XX[4]

1

ND

ND

ND

ND

ND

ND

Positive

Positive

15

53

Shiba

4.8/M

Acute Mono Leuk

45,XY,-7[1]/45,sl,t(3;12)(q26;p13)[18]/46,XY[1]

1

ND

ND

33.9

ND

ND

Yes

ND

ND

ND

57

Van de Loosdrecht

70/M

t-MDS-EB

46,XY,t(3;12)(q26;p13)[19]/46,XY[3]

1

8

ND

24.3

7.4

212

ND

Positive

Positive

42

3

Doorn-Khosrovani

NA

t-MDS-EB

46,X?,t(3;12)(q26;p13)

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

18

Haferlach

57/M

MDS

46,XY,t(3;12)(q26;p13)[19]/46,XY[1]

1

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

19

Haferlach

64/M

MDS

46,XY,t(3;12)(q26;p13),del(7)(q12)[17]/46,XY[3]

2

ND

ND

ND

ND

ND

ND

Positive

Positive

ND

5

Beyer

43/M

MDS

46,XY,t(3;12)(q26;p13)[2]/46, idem, i(14)(q10)[31]/46,XY[3]

2

ND

ND

ND

ND

ND

ND

ND

ND

ND

38

Orciuolo

35/M

MDS

t(3;12)(q26.2;p13)

1

ND

ND

ND

ND

103

ND

ND

ND

24

58

Yamamoto

21/M

MDS

46,XY,t(3;12)(q26.2;p13)[11]/46,XY[9]; 5 years later: 6,XY,t(3;12)(q26.2;p13)[7]/46,sl,del(5)(q?)[13]

after BMT: 46,XY,t(3;12)(q26.2;p13),del(7)(q?) [18]/46,sl,-Y,add(2)(q31), del(6)(q?),add(10)(q22)x2,add(21) (q22),þmar1[2]

1

2.4

0

4.1

13.9

86

Yes

Positive

Positive

66.1

55

Voutsadakis

36/F

MDS

t(3;12)(q26;p13); 3.17 years later: t(3;12)(q26;p13),+22

1

ND

ND

6.5

6

91

ND

Positive

Positive

9

54

Taylor

47/F

MDS/MPN-RS-T

t(3;12)(q26;p13)

1

ND

ND

ND

ND

ND

ND

ND

ND

ND

6

Bobadilla

49/M

CML, BCR-ABL1-positive, AP

49,XY,t(3;12)(q26.2;p13),+8,t(9;22)(q34.1;q11.2),+der(12)t(3;12),+der(22)t(9;22)(q34.1;q11.2)[21]

> 3

ND

ND

ND

ND

ND

ND

Positive

ND

ND

36

Nakamura

26/M

CML, BCR-ABL1-positive, AP

46,XY,t(3;12)(q26.2;p13),t(9;22)(q34;q11)

2

1.8

1.2

600

12.4

453

Yes

ND

ND

ND

2

Bacher

38/F

CML, BCR-ABL1-positive, BP

46,XX,t(3;12)(q26;p13),t(9;22)(q34;q11)

2

73

ND

ND

ND

ND

ND

ND

ND

ND

39

Paquette

55/M

CML, BCR-ABL1-positive, BP

47,XY,t(3;12)(q26;p13),t(7;9;22)(p15;q34;q11.2),+21[8]/46,XX[12]

> 3

ND

ND

ND

ND

ND

ND

Positive

ND

55

48

Raynaud

20/M

CML, BCR-ABL1-positive, BP

46,XY,t(9;22)(q34;q11)[3]/46, idem,t(3;12)(q26;p13)[20]

2

30

23

16.5

5

92

ND

Positive

Positive

12

40

Peeters

26/M

aCML, BCR-ABL1-negative, BP

46,XY,t(3;12)(q26;p13),t(9;15;l2)(p21;q15;pl3)

2

25

ND

64

8.7

37

Yes

Positive

Positive

ND

  1. M male, F female, Age age at initial diagnosis in years, # CG Abn number of cytogenetic abnormalities, WBC white blood cells, K 1000, µl microliter, Hgb hemoglobin, g/dl grams per deciliter, Plt platelets, PB peripheral blood, BM bone marrow, OS overall survival in months, SCT hematopoietic stem cell transplant, ND not determined, AML acute myeloid leukemia, AML w/o mat acute myeloid leukemia without maturation, AML w/mat acute myeloid leukemia with maturation, AMML acute myelomonocytic leukemia, AML-MRC acute myeloid leukemia with myelodysplasia-related changes, Acute Mono Leuk acute monoblastic leukemia, Acute Meg Leuk acute megakaryoblastic leukemia, t-AML therapy-related acute myeloid leukemia, MDS-EB2 myelodysplastic syndrome with excess blasts 2, t-MDS-EB2 therapy-related myelodysplastic syndrome with excess blasts 2, MDS myelodysplastic syndrome, t-MDS therapy-related myelodysplastic syndrome, MDS/MPN-RS-T myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis, PMF primary myelofibrosis, CML chronic myeloid leukemia, BCR-ABL1-positive, aCML atypical chronic myeloid leukemia, BP blast phase, CP chronic phase, NOS not otherwise specified, MPAL mixed-phenotype acute leukemia T/myeloid not otherwise specified, OS overall survival.
Back to article page